Skip to main content

Table 1 Baseline characteristics and clinical data of the study population

From: Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Parameter

All patients

Pirfenidone

Placebo

(n = 267)

(n = 163)

(n = 104)

Gender

   

 Male, n (%)

213 (79.8%)

132 (81.0%)

81 (77.9%)

 Female, n (%)

54 (20.2%)

31 (19.0%)

23 (22.1%)

Age, year

64.8 (6.9)

64.9 (6.7)

64.7 (7.3)

 

(n = 267)

(n = 163)

(n = 104)

BMI

24.3 (3.0)

24.1 (2.9)

24.6 (3.2)

 

(n = 267)

(n = 163)

(n = 104)

Smoking

   

 Current and former, n (%)

212 (79.4%)

129 (79.1%)

83 (79.8%)

 Never, n (%)

55 (20.6%)

34 (20.9%)

21 (20.2%)

Dyspnea scale (modified by Fletcher)

 1, n (%)

53 (19.9%)

33 (20.2%)

20 (19.2%)

 2, n (%)

143 (53.6%)

80 (49.1%)

63 (60.6%)

 3, n (%)

71 (26.6%)

50 (30.7%)

21 (20.2%)

 4 and 5, n (%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

PaO2, Torr

80.7 (9.6)

80.5 (9.6)

81.0 (9.5)

 

(n = 265)

(n = 161)

(n = 104)

AaDO2, Torr

17.7 (10.3)

17.9 (10.7)

17.4 (9.7)

 

(n = 265)

(n = 161)

(n = 104)

Lowest SpO2 during a 6MET, %

89.0 (2.2)

89.0 (2.3)

89.0 (2.0)

 

(n = 266)

(n = 162)

(n = 104)

VC, L

2.44 (0.67)

2.41 (0.65)

2.47 (0.70)

 

(n = 265)

(n = 161)

(n = 104)

%VC, %

77.8 (17.4)

76.9 (17.4)

79.1 (17.4)

 

(n = 265)

(n = 161)

(n = 104)

%DLCO, %

53.6 (17.8)

52.6 (17.6)

55.2 (18.2)

 

(n = 264)

(n = 161)

(n = 103)

Serum SP-D, ng/mL

238.8 (156.8)

231.6 (140.8)

250.1 (179.1)

 

(n = 267)

(n = 163)

(n = 104)

Serum SP-A, ng/mL

93.2 (51.6)

92.5 (43.8)

94.3 (62.0)

 

(n = 267)

(n = 163)

(n = 104)

Serum KL-6, U/mL

1317.0 (800.3)

1318.2 (803.1)

1315.0 (799.6)

 

(n = 267)

(n = 163)

(n = 104)

  1. Data are presented as n (%), or mean (SD)
  2. BMI body mass index, PaO2 partial pressure of oxygen in arterial blood, AaDO2 alveolar–arterial oxygen difference, SpO2 peripheral capillary oxygen saturation, 6MET 6-min steady-state exercise test, VC vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, SP surfactant protein, KL Krebs von den Lungen